We recently found that the have activity of the combination of Chk1 and Wee1 inhibitors is strikingly effective in preclinical models of MCL, at extremely low doses, providing a strong rational for its possible successful application in the clinical setting for this disease [24]. This evidence concerns the gene CHEK1 and mantle cell lymphoma.